Product Description: Farudodstat (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice[1][2].
Applications: Cancer-programmed cell death
Formula: C19H14F2N2O3
References: [1]Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure and Function Tällberg, 14-17 June 2019/[2]Jianbiao Zhou, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2019 Nov7;haematol.2019.230482.
CAS Number: 1035688-66-4
Molecular Weight: 356.32
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : 125 mg/mL (ultrasonic)
Target: Apoptosis;Dihydroorotate Dehydrogenase;DNA/RNA Synthesis
Deutsch
English
